Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Long-term Follow-up Study of Patients in the Clinical Trials for Spinal Muscular Atrophy Receiving AVXS-101

NCT04042025 is registered in ClinicalTrials.gov with Novartis Gene Therapies as lead sponsor.

NCT NCT04042025
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04042025 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Long-term Follow-up Study of Patients in the Clinical Trials for Spinal Muscular Atrophy Receiving AVXS-101
Lead sponsor
Novartis Gene Therapies
Phase
Phase 3
Overall status
Active, not recruiting
Start date
February 10, 2020
Completion date
December 31, 2035
Enrollment
85 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

sma, spinal muscular atrophy type i, spinal muscular atrophy type ii, spinal muscular atrophy type iii